[New triptan preparations can help the migraine patient. Pharmacodynamic and pharmacokinetic progresses].
Migraine is an idiopathic, recurrent neurovascular headache disorder characterised by attacks of debilitating pain associated with photophobia, phonophobia, nausea and vomiting. It is apparently a global disorder, occurring in all races, cultures and geographical locations. Migraine has a hereditary component, and its life-time prevalence is about 16%. About a third of migraine patients in Sweden seem to be particularly sorely afflicted having 1-6 severe attacks a month and accounting for more than 80 per cent of the annual total of about 14 million attacks in the country as a whole. In general, these migraine sufferers do not obtain satisfactory relief from simple analgesice or NSAIDs (non-sterodial antiinflammatory drugs only), and thus require additional migraine-specific treatment. Selective 5-HT1B/1D-agonists, the so-called triptans, have become an invaluable addition to the therapeutic arsenal for treating this category of patients.
Dahlöf
C G
CG
Migränklinik-Göteborg.
D000700:Analgesics / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology; D003362:Cost-Benefit Analysis; D004359:Drug Therapy, Combination; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D018170:Sumatriptan / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology; D014662:Vasoconstrictor Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology
D000700:Analgesics; D017366:Serotonin Receptor Agonists; D014662:Vasoconstrictor Agents; D018170:Sumatriptan
Nya triptanpreparat kan hjälpa migränpatienten. Farmakodynamiska och farmakokinetiska framsteg.